Drug Profile
Cefepime/enmetazobactam - Allecra Therapeutics
Alternative Names: AAI-101/cefepime - Allecra Therapeutics; AAI-202; Cefepime hydrochloride monohydrate/enmetazobactam - Allecra Therapeutics; Cefepime/AAI-101 - Allecra Therapeutics; EMT/FEP; Enmetazobactam/cefepime - Allecra Therapeutics; Enmetazobactam/cefepime hydrochloride monohydrate - Allecra Therapeutics; EXBLIFEP; FEP/AAI101; FEP/EMTLatest Information Update: 16 Apr 2024
Price :
$50
*
At a glance
- Originator Allecra Therapeutics
- Developer ADVANZ PHARMA; Allecra Therapeutics
- Class Anti-infectives; Antibacterials; Aza compounds; Beta-lactams; Carboxylic acids; Cephalosporins; Heterocyclic bicyclo compounds; Imines; Penicillins; Small molecules; Sulfones; Triazoles
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Nosocomial pneumonia; Urinary tract infections